AAPL294.38+5.02 (+1.73%) ▲|ABBV251.06-0.58 (-0.23%) ▼|ABT92.18+1.44 (+1.59%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE210.98+5.96 (+2.91%) ▲|AMAT650.91-72.09 (-9.97%) ▼|AMD540.88-40.03 (-6.89%) ▼|AMGN361.33-0.79 (-0.22%) ▼|AMT166.08+2.51 (+1.53%) ▲|AMZN241.70+3.36 (+1.41%) ▲|AVGO369.34-8.41 (-2.23%) ▼|AXP348.00+9.75 (+2.88%) ▲|BA218.58+2.11 (+0.97%) ▲|BAC58.36+1.38 (+2.42%) ▲|BKNG182.64+4.40 (+2.47%) ▲|BLK980.38+18.82 (+1.96%) ▲|BMY56.44-1.18 (-2.05%) ▼|BNY146.02+1.41 (+0.98%) ▲|BRK-B499.74-0.65 (-0.13%) ▼|C140.13+0.17 (+0.12%) ▲|CAT991.41-73.49 (-6.90%) ▼|CL92.76+1.08 (+1.18%) ▲|CMCSA23.73-0.82 (-3.34%) ▼|COF204.82+4.20 (+2.09%) ▲|COP103.22-0.74 (-0.71%) ▼|COST924.67-10.80 (-1.15%) ▼|CRM163.23+6.57 (+4.19%) ▲|CSCO117.01-0.45 (-0.38%) ▼|CVS104.81+1.36 (+1.31%) ▲|CVX165.69-0.07 (-0.04%) ▼|DE627.63-6.70 (-1.06%) ▼|DHR193.72+3.24 (+1.70%) ▲|DIS95.71-0.54 (-0.56%) ▼|DUK125.77-0.81 (-0.64%) ▼|EMR139.52-3.63 (-2.54%) ▼|FDX313.89+0.76 (+0.24%) ▲|GD362.86+8.62 (+2.43%) ▲|GE374.94+1.21 (+0.32%) ▲|GEV1,134.35-40.51 (-3.45%) ▼|GILD125.97-0.37 (-0.29%) ▼|GM75.52-1.56 (-2.02%) ▼|GOOG357.89+4.56 (+1.29%) ▲|GOOGL361.21+3.84 (+1.07%) ▲|GS1,019.61+8.24 (+0.81%) ▲|HD350.84-1.84 (-0.52%) ▼|HON221.75-2.15 (-0.96%) ▼|IBM286.25+5.04 (+1.79%) ▲|INTC127.02-12.61 (-9.03%) ▼|INTU267.08+6.08 (+2.33%) ▲|ISRG402.38+4.70 (+1.18%) ▲|JNJ253.98+0.01 (+0.00%) ▲|JPM334.07+6.74 (+2.06%) ▲|KO81.29+0.02 (+0.02%) ▲|LIN533.55+14.61 (+2.82%) ▲|LLY1,191.74-7.69 (-0.64%) ▼|LMT521.82+12.36 (+2.43%) ▲|LOW221.92+1.43 (+0.65%) ▲|LRCX391.26-42.07 (-9.71%) ▼|MA522.44+8.84 (+1.72%) ▲|MCD269.43-0.88 (-0.33%) ▼|MDLZ59.35+1.51 (+2.61%) ▲|MDT79.20+0.97 (+1.24%) ▲|META612.91+49.62 (+8.81%) ▲|MMM159.96-1.95 (-1.20%) ▼|MO71.54-0.41 (-0.57%) ▼|MRK125.37-3.13 (-2.44%) ▼|MS211.86+2.82 (+1.35%) ▲|MSFT384.28+11.26 (+3.02%) ▲|MU1,032.28-122.01 (-10.57%) ▼|NEE86.37-1.40 (-1.60%) ▼|NFLX74.19+2.79 (+3.91%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.80+6.52 (+6.57%) ▲|NVDA197.58-2.51 (-1.25%) ▼|ORCL142.50-4.05 (-2.76%) ▼|PEP141.16+5.76 (+4.25%) ▲|PFE23.88-0.20 (-0.83%) ▼|PG147.43+0.79 (+0.54%) ▲|PLTR125.73+9.06 (+7.77%) ▲|PM177.69-3.22 (-1.78%) ▼|QCOM181.92-2.87 (-1.55%) ▼|RTX191.78+2.05 (+1.08%) ▲|SBUX103.39+1.20 (+1.17%) ▲|SCHW95.78+3.51 (+3.80%) ▲|SO95.12-0.59 (-0.62%) ▼|SPG223.00-0.65 (-0.29%) ▼|T20.48-0.22 (-1.06%) ▼|TMO513.33+11.97 (+2.39%) ▲|TMUS173.06+5.33 (+3.18%) ▲|TSLA425.30+4.70 (+1.12%) ▲|TXN298.41+0.34 (+0.11%) ▲|UBER72.66+0.50 (+0.69%) ▲|UNH426.54+10.91 (+2.62%) ▲|UNP277.73+5.73 (+2.11%) ▲|UPS109.54+2.04 (+1.90%) ▲|USB61.96+1.56 (+2.58%) ▲|V351.08+7.99 (+2.33%) ▲|VZ41.99-0.35 (-0.83%) ▼|WFC85.94+3.30 (+3.99%) ▲|WMT108.82-4.44 (-3.92%) ▼|XOM136.28-0.44 (-0.32%) ▼|AAPL294.38+5.02 (+1.73%) ▲|ABBV251.06-0.58 (-0.23%) ▼|ABT92.18+1.44 (+1.59%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE210.98+5.96 (+2.91%) ▲|AMAT650.91-72.09 (-9.97%) ▼|AMD540.88-40.03 (-6.89%) ▼|AMGN361.33-0.79 (-0.22%) ▼|AMT166.08+2.51 (+1.53%) ▲|AMZN241.70+3.36 (+1.41%) ▲|AVGO369.34-8.41 (-2.23%) ▼|AXP348.00+9.75 (+2.88%) ▲|BA218.58+2.11 (+0.97%) ▲|BAC58.36+1.38 (+2.42%) ▲|BKNG182.64+4.40 (+2.47%) ▲|BLK980.38+18.82 (+1.96%) ▲|BMY56.44-1.18 (-2.05%) ▼|BNY146.02+1.41 (+0.98%) ▲|BRK-B499.74-0.65 (-0.13%) ▼|C140.13+0.17 (+0.12%) ▲|CAT991.41-73.49 (-6.90%) ▼|CL92.76+1.08 (+1.18%) ▲|CMCSA23.73-0.82 (-3.34%) ▼|COF204.82+4.20 (+2.09%) ▲|COP103.22-0.74 (-0.71%) ▼|COST924.67-10.80 (-1.15%) ▼|CRM163.23+6.57 (+4.19%) ▲|CSCO117.01-0.45 (-0.38%) ▼|CVS104.81+1.36 (+1.31%) ▲|CVX165.69-0.07 (-0.04%) ▼|DE627.63-6.70 (-1.06%) ▼|DHR193.72+3.24 (+1.70%) ▲|DIS95.71-0.54 (-0.56%) ▼|DUK125.77-0.81 (-0.64%) ▼|EMR139.52-3.63 (-2.54%) ▼|FDX313.89+0.76 (+0.24%) ▲|GD362.86+8.62 (+2.43%) ▲|GE374.94+1.21 (+0.32%) ▲|GEV1,134.35-40.51 (-3.45%) ▼|GILD125.97-0.37 (-0.29%) ▼|GM75.52-1.56 (-2.02%) ▼|GOOG357.89+4.56 (+1.29%) ▲|GOOGL361.21+3.84 (+1.07%) ▲|GS1,019.61+8.24 (+0.81%) ▲|HD350.84-1.84 (-0.52%) ▼|HON221.75-2.15 (-0.96%) ▼|IBM286.25+5.04 (+1.79%) ▲|INTC127.02-12.61 (-9.03%) ▼|INTU267.08+6.08 (+2.33%) ▲|ISRG402.38+4.70 (+1.18%) ▲|JNJ253.98+0.01 (+0.00%) ▲|JPM334.07+6.74 (+2.06%) ▲|KO81.29+0.02 (+0.02%) ▲|LIN533.55+14.61 (+2.82%) ▲|LLY1,191.74-7.69 (-0.64%) ▼|LMT521.82+12.36 (+2.43%) ▲|LOW221.92+1.43 (+0.65%) ▲|LRCX391.26-42.07 (-9.71%) ▼|MA522.44+8.84 (+1.72%) ▲|MCD269.43-0.88 (-0.33%) ▼|MDLZ59.35+1.51 (+2.61%) ▲|MDT79.20+0.97 (+1.24%) ▲|META612.91+49.62 (+8.81%) ▲|MMM159.96-1.95 (-1.20%) ▼|MO71.54-0.41 (-0.57%) ▼|MRK125.37-3.13 (-2.44%) ▼|MS211.86+2.82 (+1.35%) ▲|MSFT384.28+11.26 (+3.02%) ▲|MU1,032.28-122.01 (-10.57%) ▼|NEE86.37-1.40 (-1.60%) ▼|NFLX74.19+2.79 (+3.91%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.80+6.52 (+6.57%) ▲|NVDA197.58-2.51 (-1.25%) ▼|ORCL142.50-4.05 (-2.76%) ▼|PEP141.16+5.76 (+4.25%) ▲|PFE23.88-0.20 (-0.83%) ▼|PG147.43+0.79 (+0.54%) ▲|PLTR125.73+9.06 (+7.77%) ▲|PM177.69-3.22 (-1.78%) ▼|QCOM181.92-2.87 (-1.55%) ▼|RTX191.78+2.05 (+1.08%) ▲|SBUX103.39+1.20 (+1.17%) ▲|SCHW95.78+3.51 (+3.80%) ▲|SO95.12-0.59 (-0.62%) ▼|SPG223.00-0.65 (-0.29%) ▼|T20.48-0.22 (-1.06%) ▼|TMO513.33+11.97 (+2.39%) ▲|TMUS173.06+5.33 (+3.18%) ▲|TSLA425.30+4.70 (+1.12%) ▲|TXN298.41+0.34 (+0.11%) ▲|UBER72.66+0.50 (+0.69%) ▲|UNH426.54+10.91 (+2.62%) ▲|UNP277.73+5.73 (+2.11%) ▲|UPS109.54+2.04 (+1.90%) ▲|USB61.96+1.56 (+2.58%) ▲|V351.08+7.99 (+2.33%) ▲|VZ41.99-0.35 (-0.83%) ▼|WFC85.94+3.30 (+3.99%) ▲|WMT108.82-4.44 (-3.92%) ▼|XOM136.28-0.44 (-0.32%) ▼|
30 C
New York
Thursday, July 2, 2026

Tag: partner

Ampersand Capital Partners Invests in CurTec, a Global Leader in Pharma & Specialty Chemicals Bulk Packaging

Strategic partnership to accelerate U.S. growth, product innovation, and long-term value creation in life sciences supply chain. BOSTON and RIJEN, Netherlands, July 21, 2025 /PRNewswire/...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease

Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations.

CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services

Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery  SEOUL, South Korea, July 20, 2025 /PRNewswire/ -- CorestemChemon, a leading GLP-certified preclinical...

VSTS IMPORTANT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Vestis Corporation Investors with Losses in Excess of $100K to Secure Counsel Before...

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Vestis Corporation (NYSE: VSTS) between May 2, 2024 and May 6, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline.

Vierte TERA-Preisverleihung in Cambridge

Britisches Start-up-Unternehmen gewinnt den mit 1 Million US-Dollar dotierten Gold Award
Britisches Start-up-Unternehmen gewinnt den mit 1 Million US-Dollar dotierten Gold Award

TERA-Award: la quarta cerimonia di premiazione si è tenuta a Cambridge

Una startup britannica si aggiudica il Gold Award dal valore di 1 milione di dollari
Una startup britannica si aggiudica il Gold Award dal valore di 1 milione di dollari

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.

SOC Investor News: If You Have Suffered Losses in Sable Offshore Corp. (NYSE: SOC), You Are Encouraged to Contact The Rosen Law Firm About...

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sable Offshore Corp. (NYSE: SOC), including those who purchased shares pursuant to Sable Offshore Corp.’s May 2025 public offering, resulting from allegations that Sable Offshore Corp. may have issued materially misleading business information to the investing public.

Bragar Eagel & Squire, P.C. Reminds Investors in IRobot (IRBT) of the Class Action Lawsuit and Encourages Investors to Inquire About Their Rights

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses IRobot (IRBT) To Contact Him Directly To Discuss Their Options

PETCO ALERT: Bragar Eagel & Squire, P.C. Reminds Petco Health and Wellness Investors that a Class Action Lawsuit Has Been Filed and Encourages Investors...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Petco (WOOF) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) or Sarepta (SRPT) To Contact Him Directly To Discuss Their Options

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Petco

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Petco To Contact Him Directly To Discuss Their Options

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of iRobot Corporation

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in iRobot To Contact Him Directly To Discuss Their Options

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPartner